<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T04:05:08Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:6247555" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:6247555</identifier>
        <datestamp>2018-11-26</datestamp>
        <setSpec>ict</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article">
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Integr Cancer Ther</journal-id>
              <journal-id journal-id-type="iso-abbrev">Integr Cancer Ther</journal-id>
              <journal-id journal-id-type="publisher-id">ICT</journal-id>
              <journal-id journal-id-type="hwp">spict</journal-id>
              <journal-title-group>
                <journal-title>Integrative Cancer Therapies</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">1534-7354</issn>
              <issn pub-type="epub">1552-695X</issn>
              <publisher>
                <publisher-name>SAGE Publications</publisher-name>
                <publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC6247555</article-id>
              <article-id pub-id-type="pmcid">PMC6247555</article-id>
              <article-id pub-id-type="pmc-uid">6247555</article-id>
              <article-id pub-id-type="pmid">30027756</article-id>
              <article-id pub-id-type="pmid">30027756</article-id>
              <article-id pub-id-type="doi">10.1177/1534735418788667</article-id>
              <article-id pub-id-type="publisher-id">10.1177_1534735418788667</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Research Articles</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Acupuncture for Bortezomib-Induced Peripheral Neuropathy: Not Just
for Pain</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-4263-7272</contrib-id>
                  <name>
                    <surname>Zhi</surname>
                    <given-names>W. Iris</given-names>
                  </name>
                  <degrees>MD, PhD</degrees>
                  <xref ref-type="aff" rid="aff1-1534735418788667">1</xref>
                  <xref ref-type="author-notes" rid="fn1-1534735418788667">*</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-3019-8455</contrib-id>
                  <name>
                    <surname>Ingram</surname>
                    <given-names>Evan</given-names>
                  </name>
                  <degrees>MS</degrees>
                  <xref ref-type="aff" rid="aff2-1534735418788667">2</xref>
                  <xref ref-type="author-notes" rid="fn1-1534735418788667">*</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Li</surname>
                    <given-names>Susan Qing</given-names>
                  </name>
                  <degrees>MS</degrees>
                  <xref ref-type="aff" rid="aff1-1534735418788667">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Chen</surname>
                    <given-names>Patricia</given-names>
                  </name>
                  <degrees>BA</degrees>
                  <xref ref-type="aff" rid="aff1-1534735418788667">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Piulson</surname>
                    <given-names>Lauren</given-names>
                  </name>
                  <degrees>BS</degrees>
                  <xref ref-type="aff" rid="aff1-1534735418788667">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Bao</surname>
                    <given-names>Ting</given-names>
                  </name>
                  <degrees>MD, DABMA, MS</degrees>
                  <xref ref-type="aff" rid="aff1-1534735418788667">1</xref>
                  <xref ref-type="corresp" rid="corresp1-1534735418788667"/>
                </contrib>
              </contrib-group>
              <aff id="aff1-1534735418788667"><label>1</label>Memorial Sloan Kettering Cancer Center,
New York, NY, USA</aff>
              <aff id="aff2-1534735418788667"><label>2</label>University of Toledo, Toledo, OH,
USA</aff>
              <author-notes>
                <corresp id="corresp1-1534735418788667">Ting Bao, Integrative Medicine Service,
Memorial Sloan Kettering Cancer Center, 1429 First Avenue, New York, NY 10021,
USA. Email: <email>baot@mskcc.org</email></corresp>
                <fn fn-type="other" id="fn1-1534735418788667">
                  <label>*</label>
                  <p>Co-first authors, equal contribution.</p>
                </fn>
              </author-notes>
              <pub-date pub-type="epub">
                <day>20</day>
                <month>7</month>
                <year>2018</year>
              </pub-date>
              <pub-date pub-type="collection">
                <month>12</month>
                <year>2018</year>
              </pub-date>
              <volume>17</volume>
              <issue>4</issue>
              <fpage>1079</fpage>
              <lpage>1086</lpage>
              <history>
                <date date-type="received">
                  <day>24</day>
                  <month>2</month>
                  <year>2018</year>
                </date>
                <date date-type="rev-recd">
                  <day>27</day>
                  <month>5</month>
                  <year>2018</year>
                </date>
                <date date-type="accepted">
                  <day>18</day>
                  <month>6</month>
                  <year>2018</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© The Author(s) 2018</copyright-statement>
                <copyright-year>2018</copyright-year>
                <copyright-holder content-type="sage">SAGE Publications Inc unless otherwise noted.
Manuscript content on this site is licensed under Creative Commons
Licenses</copyright-holder>
                <license license-type="creative-commons" xlink:href="http://www.creativecommons.org/licenses/by-nc/4.0/">
                  <license-p>This article is distributed under the terms of the Creative Commons
Attribution-NonCommercial 4.0 License (<ext-link ext-link-type="uri" xlink:href="http://www.creativecommons.org/licenses/by-nc/4.0/">http://www.creativecommons.org/licenses/by-nc/4.0/</ext-link>) which
permits non-commercial use, reproduction and distribution of the work
without further permission provided the original work is attributed as
specified on the SAGE and Open Access pages (<ext-link ext-link-type="uri" xlink:href="https://us.sagepub.com/en-us/nam/open-access-at-sage">https://us.sagepub.com/en-us/nam/open-access-at-sage</ext-link>).</license-p>
                </license>
              </permissions>
              <abstract>
                <p><bold>Background:</bold> Bortezomib-induced peripheral neuropathy (BIPN) is a
common and debilitating side effect. Our pilot study demonstrated that
acupuncture is safe and can decrease total neuropathic symptoms. However, there
is lack of knowledge in which individual BIPN symptoms benefited from
acupuncture. <bold>Purpose:</bold> To characterize individual symptoms reduced
by acupuncture in patients with BIPN. <bold>Methods:</bold> Patients with
multiple myeloma treated with bortezomib who developed BIPN grade 2 or above,
based on National Cancer Institute Common Terminology Criteria for Adverse
Events (NCI CTCAE), were enrolled and received 10 acupuncture treatments over 10
weeks. Self-reported BIPN-associated symptoms assessments were collected weekly
at baseline, during, and after acupuncture treatment using the Neuropathy Pain
Scale (NPS) and the Functional Assessment of Cancer Therapy/Gynecologic Oncology
Group–Neurotoxicity (FACT/GOG-Ntx) questionnaires. Changes in individual
symptoms were analyzed based on FACT/GOG-Ntx and NPS scores.
<bold>Results:</bold> There were statistically significant reductions in
individual symptoms in both NPS and FACT/GOG-Ntx. The FACT/GOG-Ntx reductions
were most pronounced in hand/feet numbness/tingling, discomfort, and trouble
walking. The sensory symptoms, such as tingling and numbness, especially in the
feet, reduced the most (<italic>P</italic> &lt; .0001), and motor dysfunction
also reduced significantly (<italic>P</italic> = .0001). Both hearing and
dysfunction scores were also statistically significantly increased, indicating
improved symptoms. The NPS scores showed significant symptom relief in all 10
items from the NPS assessment, particularly in cold sensitivity and an
unpleasant feeling. <bold>Conclusions:</bold> Acupuncture can improve multiple
symptoms associated with BIPN, particularly numbness and tingling in hands and
feet, cold sensitivity, and an unpleasant feeling. Further randomized control
trials are warranted to confirm our findings.</p>
              </abstract>
              <kwd-group>
                <kwd>acupuncture</kwd>
                <kwd>bortezomib</kwd>
                <kwd>multiple myeloma</kwd>
                <kwd>peripheral neuropathy</kwd>
              </kwd-group>
              <funding-group>
                <award-group id="award1-1534735418788667">
                  <funding-source id="funding1-1534735418788667">
                    <institution-wrap>
                      <institution>Memorial Sloan-Kettering Cancer Center</institution>
                      <institution-id institution-id-type="FundRef">https://doi.org/10.13039/100007052</institution-id>
                    </institution-wrap>
                  </funding-source>
                  <award-id rid="funding1-1534735418788667">P30-CA008748</award-id>
                </award-group>
                <award-group id="award2-1534735418788667">
                  <funding-source id="funding2-1534735418788667">
                    <institution-wrap>
                      <institution>National Cancer Institute</institution>
                      <institution-id institution-id-type="FundRef">https://doi.org/10.13039/100000054</institution-id>
                    </institution-wrap>
                  </funding-source>
                  <award-id rid="funding2-1534735418788667">R21CA173263</award-id>
                </award-group>
              </funding-group>
            </article-meta>
          </front>
          <body>
            <sec sec-type="intro" id="section1-1534735418788667">
              <title>Introduction</title>
              <p>Bortezomib is an effective therapy for patients with multiple myeloma (MM). However,
more than one third of patients develop bortezomib-induced peripheral neuropathy
(BIPN), requiring dose reduction or treatment interruptions, leading to adverse
patient outcomes.<sup><xref rid="bibr1-1534735418788667" ref-type="bibr">1</xref><xref rid="bibr2-1534735418788667" ref-type="bibr"/><xref rid="bibr3-1534735418788667" ref-type="bibr"/>-<xref rid="bibr4-1534735418788667" ref-type="bibr">4</xref></sup> In addition, BIPN can last for
years after bortezomib discontinuation and have a significant negative impact on
quality of life.<sup><xref rid="bibr3-1534735418788667" ref-type="bibr">3</xref></sup> BIPN usually presents as both sensory and motor neuropathies, such as
paresthesia (tingling, burning sensation), hyperalgesia (increased sensitivity to
noxious stimulation) or allodynia (pain that results from a normally innocuous
stimulation), distal sensory loss, and reduced deep tendon reflexes.<sup><xref rid="bibr5-1534735418788667" ref-type="bibr">5</xref></sup> The treatment for BIPN is mainly limited to pharmacological interventions
such as opioids, gabapentin, and duloxetine. However, these medications often have
limited effectiveness and undesirable adverse effects,<sup><xref rid="bibr6-1534735418788667" ref-type="bibr">6</xref><xref rid="bibr7-1534735418788667" ref-type="bibr"/>-<xref rid="bibr8-1534735418788667" ref-type="bibr">8</xref></sup> creating the unmet need to
explore complementary treatment options.</p>
              <p>Acupuncture, a traditional Chinese medical technique in which needles are inserted
into certain points on the body, has demonstrated benefits to neuropathic pain in
patients with diabetes,<sup><xref rid="bibr9-1534735418788667" ref-type="bibr">9</xref></sup> cancer,<sup><xref rid="bibr10-1534735418788667" ref-type="bibr">10</xref></sup> and other conditions. Different acupuncture techniques, for example,
auricular acupuncture, have been shown to decrease pain intensity, while more
standard reference points for needle insertion have also demonstrated neuropathic
symptom improvement in cancer patients.<sup><xref rid="bibr9-1534735418788667" ref-type="bibr">9</xref>,<xref rid="bibr11-1534735418788667" ref-type="bibr">11</xref><xref rid="bibr12-1534735418788667" ref-type="bibr"/><xref rid="bibr13-1534735418788667" ref-type="bibr"/><xref rid="bibr14-1534735418788667" ref-type="bibr"/><xref rid="bibr15-1534735418788667" ref-type="bibr"/>-<xref rid="bibr16-1534735418788667" ref-type="bibr">16</xref></sup> Reviews of integrative
oncology services at our institution found that approximately one third of the
patients receiving acupuncture are treated for peripheral neuropathy,<sup><xref rid="bibr17-1534735418788667" ref-type="bibr">17</xref></sup> suggesting the need for continued research of its effectiveness.</p>
              <p>Our prior single-arm pilot study showed that acupuncture was safe and potentially
effective in reducing BIPN-associated pain and improving function, supporting the
need for further research. The study focused on the feasibility and safety of
acupuncture and reported the overall assessment results as the secondary objective.<sup><xref rid="bibr11-1534735418788667" ref-type="bibr">11</xref></sup> In this report, through validated Neuropathy Pain Scale (NPS) and Functional
Assessment of Cancer Therapy/Gynecologic Oncology Group–Neurotoxicity (FACT/GOG-Ntx)
questionnaires, we investigated the effect of acupuncture on individual
self-reported BIPN symptoms.</p>
            </sec>
            <sec sec-type="methods" id="section2-1534735418788667">
              <title>Methods</title>
              <sec id="section3-1534735418788667">
                <title>Patients</title>
                <p>Patients with MM who received bortezomib and developed persistent BIPN of grade 2
or higher were eligible for the study; no acupuncture was allowed within 1 month
prior to enrollment. The grading system is based on National Cancer Institute
Common Toxicity Criteria Adverse Event and defined as follows: grade 1,
paresthesias or areflexia without pain or loss of function; grade 2,
symptomatic, interferes with function but not daily living activities; grade 3,
symptomatic, interferes with daily living activities; and grade 4, sensorimotor
neuropathy that significantly interfere with daily living activities. A detailed
recruitment plan and exclusion criteria were described in our previous publication.<sup><xref rid="bibr11-1534735418788667" ref-type="bibr">11</xref></sup> Written consent was provided by each of the 27 patients before enrollment
into the clinical trial. The trial was approved by the institutional review
board at the University of Maryland and registered at <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov">clinicaltrials.gov</ext-link> (NCT01541644).</p>
              </sec>
              <sec id="section4-1534735418788667">
                <title>Interventions</title>
                <p>All patients received 10 acupuncture treatments: twice weekly for the first 2
weeks, weekly for 4 weeks, and then biweekly for 4 weeks. The acupuncture
treatments were performed by a licensed acupuncturist with 8 years of
experience. All acupuncture points were selected for their analgesic
characteristics and effectiveness in treating pain, swelling, and numbness (Yin
Yang House, 2013). Points included bilateral ear points (Shen men, point zero,
and 2 additional auricular acupuncture points where electrodermal signal was
detected), bilateral body acupuncture points (LI4, TE5, LI11, ST40), and Ba Feng
located in upper and lower extremities were selected, and procedures were
described in detail in our previous publication.<sup><xref rid="bibr11-1534735418788667" ref-type="bibr">11</xref></sup> The de qi, a sense of aching pain, soreness, and heaviness, was achieved
in certain acupuncture points (LI4, LI11, and ST40). All patients continued
their previously prescribed peripheral neuropathy medications and were
encouraged to avoid any changes for the duration of the study.</p>
              </sec>
              <sec id="section5-1534735418788667">
                <title>Peripheral Neuropathy Assessments</title>
                <p>Patients were assessed for self-reported signs and symptoms of neuropathy using
FACT/GOG-Ntx and NPS. The FACT/GOG-Ntx is an 11-item neurotoxicity subscale to
assess patients’ symptoms from neuropathy. The score includes sensory
neuropathy, motor neuropathy, hearing neuropathy, and dysfunction associated
with neuropathy. The FACT/GOG-Ntx symptoms include numbness and tingling in the
hands (Ntx 1) and feet (Ntx 2), discomfort in the hands (Ntx 3) and feet (Ntx
4), joint pain/muscle cramps (Ntx 5), feeling weak all over (HI 12), trouble
hearing (Ntx 6), ringing/buzzing in the ears (Ntx 7), trouble buttoning buttons
(Ntx 8), trouble feeling the shape of small objects (Ntx 9), and trouble walking
(AN 6).<sup><xref rid="bibr18-1534735418788667" ref-type="bibr">18</xref>,<xref rid="bibr19-1534735418788667" ref-type="bibr">19</xref></sup> The
sensory subscale includes Ntx1 to 4; the hearing subscale includes Ntx 6 to 7;
the motor subscale includes Ntx 5, HI 12, and AN 6; and the dysfunction subscale
consists of Ntx 8 to 9. The FACT/GOG-Ntx has been demonstrated as valid,
reliable, and sensitive to meaningful clinical distinctions over time.<sup><xref rid="bibr20-1534735418788667" ref-type="bibr">20</xref></sup> The scores were standardized, the resulting cumulative scores range from
0 to 44, with higher scores indicating less neuropathy.</p>
                <p>The NPS is a multidimensional tool with self-reported visual analogue to define
pain intensities and associated characteristics. The 10 items of NPS consist of
2 global pain domains (pain intensity and unpleasantness), 6 specific pain
qualities (sharp, dull, sensitive, hot, cold, and itchy pain), and 2 spatial
qualities (deep and surface pain).<sup><xref rid="bibr15-1534735418788667" ref-type="bibr">15</xref></sup> With each item scored from 0 to 10, NPS has a cumulative score ranging
from 0 to 100. The higher NPS scores indicate worse neuropathic pain symptoms
and lower NPS scores indicate less neuropathic pain symptoms.</p>
                <p>Both FACT/GOG-Ntx and NPS assessments were administered before the first
acupuncture treatment (baseline/week 0), during weeks of 1, 2, 3, 4, 5, 6, 8,
and 10 (end of treatment), as well as at 4-week follow-up (week 14).</p>
              </sec>
              <sec id="section6-1534735418788667">
                <title>Data Analysis</title>
                <p>Mean FACT/GOG-Ntx and NPS individual item scores were calculated for each week.
We used 1-way repeated measures analysis of variance to determine if there were
differences in FACT/GOG-Ntx and NPS individual item and domain scores among
enrolled subjects over the 14 weeks due to acupuncture treatment. Statistical
analyses were conducted using STATA 12 (STATA Corp, College Station, TX). All
analyses were 2-sided, with <italic>P &lt;</italic> .05 indicating
significance.</p>
              </sec>
            </sec>
            <sec sec-type="results" id="section7-1534735418788667">
              <title>Results</title>
              <p>Forty-six MM patients were screened between May 2011 and February 2012. Of 27
eligible patients, all 27 were consented and enrolled in the study (<xref rid="table1-1534735418788667" ref-type="table">Table 1</xref>). The previously
published pilot study detailed both patient enrollment and completion.<sup><xref rid="bibr11-1534735418788667" ref-type="bibr">11</xref></sup> The pharmacological interventions for neuropathy included narcotics (n = 13),
gabapentin (n = 12), amitriptyline (n = 3), pregabalin (n = 2), and duloxetine (n =
2). During the study, 22 of the 27 patients remained on the same dose of medication,
while 3 patients increased narcotic dosage and 2 decreased.</p>
              <table-wrap id="table1-1534735418788667" orientation="portrait" position="float">
                <label>Table 1.</label>
                <caption>
                  <p>Baseline Characteristics of the 27 Enrolled Patients (Bao et al<sup><xref rid="bibr11-1534735418788667" ref-type="bibr">11</xref></sup>).</p>
                </caption>
                <alternatives>
                  <graphic xlink:href="10.1177_1534735418788667-table1"/>
                  <table frame="hsides" rules="groups">
                    <colgroup span="1">
                      <col align="left" span="1"/>
                      <col align="char" char="." span="1"/>
                    </colgroup>
                    <tbody>
                      <tr>
                        <td rowspan="1" colspan="1">Median age</td>
                        <td rowspan="1" colspan="1">63 years (range = 49-77)</td>
                      </tr>
                      <tr>
                        <td colspan="2" rowspan="1">Race, n (%)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Caucasian</td>
                        <td rowspan="1" colspan="1">17 (63%)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> African-American</td>
                        <td rowspan="1" colspan="1">9 (33%)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Median BMI</td>
                        <td rowspan="1" colspan="1">32 (range = 24-49)</td>
                      </tr>
                      <tr>
                        <td colspan="2" rowspan="1">Peripheral neuropathy grade, n (%)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> 2</td>
                        <td rowspan="1" colspan="1">12 (44%)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> 3</td>
                        <td rowspan="1" colspan="1">14 (52%)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> 4</td>
                        <td rowspan="1" colspan="1">1 (4%)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Acute painful peripheral neuropathy, n (%)</td>
                        <td rowspan="1" colspan="1">8 (9%)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Median months after drug discontinuation</td>
                        <td rowspan="1" colspan="1">19 (range = 1-83)</td>
                      </tr>
                      <tr>
                        <td colspan="2" rowspan="1">Multiple myeloma status at enrollment, n (%)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Remission</td>
                        <td rowspan="1" colspan="1">19 (70%)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Progression</td>
                        <td rowspan="1" colspan="1">8 (30%)</td>
                      </tr>
                    </tbody>
                  </table>
                </alternatives>
                <table-wrap-foot>
                  <fn id="table-fn1-1534735418788667">
                    <p>Abbreviation: BMI, body mass index.</p>
                  </fn>
                </table-wrap-foot>
              </table-wrap>
              <p>The analysis of all 11 items of the FACT/GOG-Ntx demonstrated increasing scores from
baseline (week 0) through the end of treatment (week 10) that continued to increase
after completion of treatment (week 14; <xref rid="table2-1534735418788667" ref-type="table">Table 2</xref>). The higher FACT/GOG-Ntx scores
reported at the 4-week posttreatment follow-up (Week 14) indicate a reduction in
peripheral neuropathy-associated symptoms as well as an improvement in function. All
4 FACT/GOG-Ntx subscale domains (sensory, motor, hearing, and dysfunction) increased
from baseline, during acupuncture treatment, and through posttreatment follow-up at
week 14 (<xref ref-type="fig" rid="fig1-1534735418788667">Figure 1</xref>). The
sensory score increased more than 4 points over 14 weeks (5.48 to 9.88,
<italic>P</italic> &lt; .0001), and the motor score also increased from 6.89 to
8.38 (<italic>P</italic> = .0001). Hearing and dysfunction scores also increased
with statistical significance, indicating improved symptoms. After breaking down
each individual symptoms, the mean score of numbness and tingling in hands increased
from 1.85 to 2.67 (<italic>P</italic> &lt; .0001), and the mean score of numbness
and tingling in feet increased from 0.7 at baseline to 2.13 at week 14
(<italic>P</italic> &lt; .0001). The discomfort in both hands and feet were
lessened with statistical significance. This was more noticeable in foot discomfort,
as the mean score increased from 0.81 to 2.25 (<italic>P</italic> &lt; .0001). The
motor symptoms, including joint pain/muscle cramps and feeling “weak all over,” also
increased over time but were not statistically significant (<italic>P</italic> = .41
and .26, respectively). A similar trend was observed among the hearing-related
symptoms, with higher reported scores for trouble hearing and ringing/buzzing in
ears during 10 weeks of acupuncture that remained elevated at week 14, although
these were not statistically different from week 0 (<italic>P</italic> = .058 and
.36, respectively). Dysfunction associated with BIPN, such as trouble with buttons,
difficulty with sensing the shape of small objects, and trouble walking all scored
higher at week 14, which indicated significant improvement in walking (mean score
from 1.67 to 2.5, <italic>P</italic> &lt; .0001) and buttoning buttons
(<italic>P</italic> = .0016). These results suggested that acupuncture
significantly improved debilitating symptoms associated with BIPN.</p>
              <table-wrap id="table2-1534735418788667" orientation="portrait" position="float">
                <label>Table 2.</label>
                <caption>
                  <p>Weekly FACT/GOG-Ntx Individual and Subscale Item Averages With Standard
Deviations (SD).</p>
                </caption>
                <alternatives>
                  <graphic xlink:href="10.1177_1534735418788667-table2"/>
                  <table frame="hsides" rules="groups">
                    <colgroup span="1">
                      <col align="left" span="1"/>
                      <col align="char" char="." span="1"/>
                      <col align="char" char="." span="1"/>
                      <col align="char" char="." span="1"/>
                      <col align="char" char="." span="1"/>
                      <col align="char" char="." span="1"/>
                      <col align="char" char="." span="1"/>
                      <col align="char" char="." span="1"/>
                      <col align="char" char="." span="1"/>
                      <col align="char" char="." span="1"/>
                      <col align="char" char="." span="1"/>
                      <col align="char" char="." span="1"/>
                    </colgroup>
                    <thead>
                      <tr>
                        <th rowspan="1" colspan="1"/>
                        <th align="center" rowspan="1" colspan="1">Week 0 Mean (SD) (n = 27)</th>
                        <th align="center" rowspan="1" colspan="1">Week 1 Mean (SD) (n = 18)</th>
                        <th align="center" rowspan="1" colspan="1">Week 2 Mean (SD) (n = 24)</th>
                        <th align="center" rowspan="1" colspan="1">Week 3 Mean (SD) (n = 24)</th>
                        <th align="center" rowspan="1" colspan="1">Week 4 Mean (SD) (n = 23)</th>
                        <th align="center" rowspan="1" colspan="1">Week 5 Mean (SD) (n = 23)</th>
                        <th align="center" rowspan="1" colspan="1">Week 6 Mean (SD) (n = 22)</th>
                        <th align="center" rowspan="1" colspan="1">Week 8 Mean (SD) (n = 21)</th>
                        <th align="center" rowspan="1" colspan="1">Week 10 Mean (SD) (n = 20)</th>
                        <th align="center" rowspan="1" colspan="1">Week 14 Mean (SD) (n = 24)</th>
                        <th align="center" rowspan="1" colspan="1">
                          <italic>P</italic>
                        </th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td rowspan="1" colspan="1">Ntx 1: Hands numbness/tingling</td>
                        <td rowspan="1" colspan="1">1.85 (1.46)</td>
                        <td rowspan="1" colspan="1">2.06 (0.21)</td>
                        <td rowspan="1" colspan="1">2.29 (1.16)</td>
                        <td rowspan="1" colspan="1">2.38 (1.21)</td>
                        <td rowspan="1" colspan="1">2.57 (1.08)</td>
                        <td rowspan="1" colspan="1">2.57 (0.99)</td>
                        <td rowspan="1" colspan="1">2.68 (1.04)</td>
                        <td rowspan="1" colspan="1">2.52 (1.17)</td>
                        <td rowspan="1" colspan="1">2.7 (1.03)</td>
                        <td rowspan="1" colspan="1">2.67 (1)</td>
                        <td rowspan="1" colspan="1">
                          <bold>&lt;.0001</bold>
                        </td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Ntx 2: Feet numbness/tingling</td>
                        <td rowspan="1" colspan="1">0.7 (1.27)</td>
                        <td rowspan="1" colspan="1">1.44 (1.54)</td>
                        <td rowspan="1" colspan="1">1.33 (1.24)</td>
                        <td rowspan="1" colspan="1">1.58 (1.28)</td>
                        <td rowspan="1" colspan="1">1.83 (1.23)</td>
                        <td rowspan="1" colspan="1">1.78 (1.2)</td>
                        <td rowspan="1" colspan="1">2 (1.27)</td>
                        <td rowspan="1" colspan="1">2 (1.05)</td>
                        <td rowspan="1" colspan="1">2.05 (1.15)</td>
                        <td rowspan="1" colspan="1">2.13 (1.156)</td>
                        <td rowspan="1" colspan="1">
                          <bold>&lt;.0001</bold>
                        </td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Ntx 3: Hands discomfort</td>
                        <td rowspan="1" colspan="1">2.11 (1.37)</td>
                        <td rowspan="1" colspan="1">2.33 (1.08)</td>
                        <td rowspan="1" colspan="1">2.46 (1.14)</td>
                        <td rowspan="1" colspan="1">2.38 (1.38)</td>
                        <td rowspan="1" colspan="1">2.83 (1.07)</td>
                        <td rowspan="1" colspan="1">2.87 (1.06)</td>
                        <td rowspan="1" colspan="1">2.86 (1.08)</td>
                        <td rowspan="1" colspan="1">2.9 (1.18)</td>
                        <td rowspan="1" colspan="1">2.8 (1.06)</td>
                        <td rowspan="1" colspan="1">2.83 (1.01)</td>
                        <td rowspan="1" colspan="1">
                          <bold>.0001</bold>
                        </td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Ntx 4: Feet discomfort</td>
                        <td rowspan="1" colspan="1">0.81 (1.36)</td>
                        <td rowspan="1" colspan="1">1.5 (1.58)</td>
                        <td rowspan="1" colspan="1">1.13 (1.12)</td>
                        <td rowspan="1" colspan="1">1.71 (1.27)</td>
                        <td rowspan="1" colspan="1">2 (1.21)</td>
                        <td rowspan="1" colspan="1">1.96 (1.15)</td>
                        <td rowspan="1" colspan="1">2.18 (1.05)</td>
                        <td rowspan="1" colspan="1">2.14 (1.24)</td>
                        <td rowspan="1" colspan="1">2.1 (1.21)</td>
                        <td rowspan="1" colspan="1">2.25 (1.29)</td>
                        <td rowspan="1" colspan="1">
                          <bold>&lt;.0001</bold>
                        </td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Ntx 5: Joint pain/muscle cramps</td>
                        <td rowspan="1" colspan="1">2.44 (1.15)</td>
                        <td rowspan="1" colspan="1">2.67 (1.37)</td>
                        <td rowspan="1" colspan="1">2.83 (1.31)</td>
                        <td rowspan="1" colspan="1">2.79 (1.35)</td>
                        <td rowspan="1" colspan="1">2.91 (1.2)</td>
                        <td rowspan="1" colspan="1">3 (1.17)</td>
                        <td rowspan="1" colspan="1">3.18 (1.09)</td>
                        <td rowspan="1" colspan="1">3.14 (1.01)</td>
                        <td rowspan="1" colspan="1">3.1 (1.29)</td>
                        <td rowspan="1" colspan="1">2.79 (1.56)</td>
                        <td rowspan="1" colspan="1">.414</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">HI 12: Feel weak all over</td>
                        <td rowspan="1" colspan="1">2.78 (0.93)</td>
                        <td rowspan="1" colspan="1">2.72 (1.02)</td>
                        <td rowspan="1" colspan="1">3 (0.88)</td>
                        <td rowspan="1" colspan="1">2.13 (0.99)</td>
                        <td rowspan="1" colspan="1">3.22 (1.09)</td>
                        <td rowspan="1" colspan="1">3.26 (0.92)</td>
                        <td rowspan="1" colspan="1">3.41 (0.73)</td>
                        <td rowspan="1" colspan="1">3.19 (1.08)</td>
                        <td rowspan="1" colspan="1">3.45 (0.76)</td>
                        <td rowspan="1" colspan="1">3.08 (1.35)</td>
                        <td rowspan="1" colspan="1">.2611</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Ntx 6: Trouble hearing</td>
                        <td rowspan="1" colspan="1">2.96 (1.34)</td>
                        <td rowspan="1" colspan="1">3.11 (1.23)</td>
                        <td rowspan="1" colspan="1">3 (1.35)</td>
                        <td rowspan="1" colspan="1">3.41 (1.06)</td>
                        <td rowspan="1" colspan="1">3.26 (1.05)</td>
                        <td rowspan="1" colspan="1">3.26 (1.18)</td>
                        <td rowspan="1" colspan="1">3.5 (0.96)</td>
                        <td rowspan="1" colspan="1">3.29 (1.19)</td>
                        <td rowspan="1" colspan="1">3.3 (1.13)</td>
                        <td rowspan="1" colspan="1">3.38 (1.01)</td>
                        <td rowspan="1" colspan="1">.0582</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Ntx 7: Ringing/buzzing ears</td>
                        <td rowspan="1" colspan="1">3.04 (1.37)</td>
                        <td rowspan="1" colspan="1">3.33 (1.33)</td>
                        <td rowspan="1" colspan="1">3.13 (1.51)</td>
                        <td rowspan="1" colspan="1">3.25 (1.26)</td>
                        <td rowspan="1" colspan="1">3.26 (1.36)</td>
                        <td rowspan="1" colspan="1">3.39 (1.31)</td>
                        <td rowspan="1" colspan="1">3.27 (1.42)</td>
                        <td rowspan="1" colspan="1">3.24 (1.45)</td>
                        <td rowspan="1" colspan="1">3.25 (1.37)</td>
                        <td rowspan="1" colspan="1">3.29 (1.27)</td>
                        <td rowspan="1" colspan="1">.363</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Ntx 8: Trouble with buttons</td>
                        <td rowspan="1" colspan="1">2.59 (1.34)</td>
                        <td rowspan="1" colspan="1">2.33 (1.49)</td>
                        <td rowspan="1" colspan="1">2.63 (1.17)</td>
                        <td rowspan="1" colspan="1">2.88 (1.15)</td>
                        <td rowspan="1" colspan="1">2.78 (1.24)</td>
                        <td rowspan="1" colspan="1">2.78 (1.24)</td>
                        <td rowspan="1" colspan="1">2.95 (1.09)</td>
                        <td rowspan="1" colspan="1">2.76 (1.22)</td>
                        <td rowspan="1" colspan="1">2.75 (1.33)</td>
                        <td rowspan="1" colspan="1">2.79 (1.32)</td>
                        <td rowspan="1" colspan="1">
                          <bold>.0016</bold>
                        </td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Ntx 9: Trouble with small shapes</td>
                        <td rowspan="1" colspan="1">2.89 (1.37)</td>
                        <td rowspan="1" colspan="1">3 (1.14)</td>
                        <td rowspan="1" colspan="1">2.67 (1.43)</td>
                        <td rowspan="1" colspan="1">2.96 (1.12)</td>
                        <td rowspan="1" colspan="1">3 (1.21)</td>
                        <td rowspan="1" colspan="1">2.91 (1.2)</td>
                        <td rowspan="1" colspan="1">3.09 (1.02)</td>
                        <td rowspan="1" colspan="1">2.95 (1.02)</td>
                        <td rowspan="1" colspan="1">2.7 (1.34)</td>
                        <td rowspan="1" colspan="1">2.92 (1.28)</td>
                        <td rowspan="1" colspan="1">.3858</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">AN 6: Trouble walking</td>
                        <td rowspan="1" colspan="1">1.67 (1.24)</td>
                        <td rowspan="1" colspan="1">1.5 (1.09)</td>
                        <td rowspan="1" colspan="1">2.25 (1.07)</td>
                        <td rowspan="1" colspan="1">2.33 (1.31)</td>
                        <td rowspan="1" colspan="1">2.52 (1.24)</td>
                        <td rowspan="1" colspan="1">2.52 (1.12)</td>
                        <td rowspan="1" colspan="1">2.59 (1.09)</td>
                        <td rowspan="1" colspan="1">2.43 (1.16)</td>
                        <td rowspan="1" colspan="1">2.55 (1.05)</td>
                        <td rowspan="1" colspan="1">2.5 (1.22)</td>
                        <td rowspan="1" colspan="1">
                          <bold>&lt;.0001</bold>
                        </td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">FACT Sensory</td>
                        <td rowspan="1" colspan="1">5.48 (4.27)</td>
                        <td rowspan="1" colspan="1">7.33 (4.39)</td>
                        <td rowspan="1" colspan="1">7.21 (3.79)</td>
                        <td rowspan="1" colspan="1">8.04 (4.11)</td>
                        <td rowspan="1" colspan="1">9.21 (3.41)</td>
                        <td rowspan="1" colspan="1">9.17 (3.62)</td>
                        <td rowspan="1" colspan="1">9.73 (3.55)</td>
                        <td rowspan="1" colspan="1">9.57 (3.94)</td>
                        <td rowspan="1" colspan="1">9.65 (3.84)</td>
                        <td rowspan="1" colspan="1">9.88 (3.66)</td>
                        <td rowspan="1" colspan="1">
                          <bold>&lt;.0001</bold>
                        </td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">FACT Motor</td>
                        <td rowspan="1" colspan="1">6.89 (2.19)</td>
                        <td rowspan="1" colspan="1">6.89 (2.74)</td>
                        <td rowspan="1" colspan="1">8.08 (2.72)</td>
                        <td rowspan="1" colspan="1">8.25 (3.07)</td>
                        <td rowspan="1" colspan="1">8.65 (3.02)</td>
                        <td rowspan="1" colspan="1">8.78 (2.63)</td>
                        <td rowspan="1" colspan="1">9.18 (2.58)</td>
                        <td rowspan="1" colspan="1">8.76 (2.79)</td>
                        <td rowspan="1" colspan="1">9.1 (2.55)</td>
                        <td rowspan="1" colspan="1">8.38 (3.36)</td>
                        <td rowspan="1" colspan="1">
                          <bold>.0001</bold>
                        </td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">FACT Hearing</td>
                        <td rowspan="1" colspan="1">6 (2.17)</td>
                        <td rowspan="1" colspan="1">6.44 (2.15)</td>
                        <td rowspan="1" colspan="1">6.13 (2.13)</td>
                        <td rowspan="1" colspan="1">6.67 (2.06)</td>
                        <td rowspan="1" colspan="1">6.52 (2.17)</td>
                        <td rowspan="1" colspan="1">6.65 (2.12)</td>
                        <td rowspan="1" colspan="1">6.77 (2.09)</td>
                        <td rowspan="1" colspan="1">6.52 (2.36)</td>
                        <td rowspan="1" colspan="1">6.55 (2.09)</td>
                        <td rowspan="1" colspan="1">6.67 (2.09)</td>
                        <td rowspan="1" colspan="1">.014</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">FACT Dysfunction</td>
                        <td rowspan="1" colspan="1">5.48 (2.38)</td>
                        <td rowspan="1" colspan="1">5.33 (2.63)</td>
                        <td rowspan="1" colspan="1">5.29 (2.46)</td>
                        <td rowspan="1" colspan="1">5.83 (2.12)</td>
                        <td rowspan="1" colspan="1">5.78 (2.29)</td>
                        <td rowspan="1" colspan="1">5.69 (2.3)</td>
                        <td rowspan="1" colspan="1">6.04 (1.99)</td>
                        <td rowspan="1" colspan="1">5.71 (2.12)</td>
                        <td rowspan="1" colspan="1">5.45 (2.67)</td>
                        <td rowspan="1" colspan="1">5.71 (2.54)</td>
                        <td rowspan="1" colspan="1">.0378</td>
                      </tr>
                    </tbody>
                  </table>
                </alternatives>
                <table-wrap-foot>
                  <fn id="table-fn2-1534735418788667">
                    <p>Abbreviation: FACT/GOG-Ntx, Functional Assessment of Cancer
Therapy/Gynecologic Oncology Group-Neurotoxicity.</p>
                  </fn>
                  <fn id="table-fn3-1534735418788667">
                    <p>Boldface indicate values (P&lt;0.01), suggesting statistically
significant with substantial evidence against the null hypothesis.</p>
                  </fn>
                </table-wrap-foot>
              </table-wrap>
              <fig id="fig1-1534735418788667" orientation="portrait" position="float">
                <label>Figure 1.</label>
                <caption>
                  <p>FACT/GOG-Ntx domain scores (mean and 95% confidence intervals) change over
time. (The higher score, the lesser BIPN; *<italic>P</italic> &lt; .05 and
**<italic>P</italic> &lt; .001.)</p>
                </caption>
                <graphic xlink:href="10.1177_1534735418788667-fig1"/>
              </fig>
              <p>Data collected from the NPS assessment showed consistent, statistically significant
score reductions across all 10 items, which indicates reduction in neuropathic pain
symptoms after acupuncture treatment. In 6 out of 10 items, the mean NPS score
reductions before treatment (week 0) and at posttreatment follow-up (week 14) were
greater than 2 points, which is considered a clinically significant change.<sup><xref rid="bibr15-1534735418788667" ref-type="bibr">15</xref></sup> In particular, the pain intensity score had a mean score reduction of 2.42
points (<italic>P</italic> &lt; .0001), from 4.96 at baseline down to 2.54 at week
14. The unpleasant scores also significantly decreased over time from 5.63 to 2.96,
with mean score reduction of 2.67 points (<italic>P</italic> &lt; .0001). Both score
reductions suggested less pain and less unpleasant feeling associated with pain
after acupuncture therapy (<xref ref-type="fig" rid="fig2-1534735418788667">Figure
2</xref>). Among 6 specific pain qualities, hot, cold, sharp, and dull pain were
all significantly reduced (<italic>P</italic> &lt; .001), with the most significant
score reductions observed in hot and sharp sensations (<xref ref-type="fig" rid="fig2-1534735418788667">Figure 2</xref>). Sensitivity to light touch and
itchy pain scores also significantly decreased over time (<italic>P</italic> = .001
and .021, respectively). <xref rid="table3-1534735418788667" ref-type="table">Table
3</xref> displays the NPS individual item scores at each time point during the
study.</p>
              <fig id="fig2-1534735418788667" orientation="portrait" position="float">
                <label>Figure 2.</label>
                <caption>
                  <p>Selected NPS symptoms (unpleasant feeling, hot, cold, and itchiness) scores
change over time. (The lower score, the lesser BIPN; *<italic>P</italic>
&lt; .05 and **<italic>P</italic> &lt; .0001.)</p>
                </caption>
                <graphic xlink:href="10.1177_1534735418788667-fig2"/>
              </fig>
              <table-wrap id="table3-1534735418788667" orientation="portrait" position="float">
                <label>Table 3.</label>
                <caption>
                  <p>Weekly NPS Individual Items Averages With Standard Deviations (SD).</p>
                </caption>
                <alternatives>
                  <graphic xlink:href="10.1177_1534735418788667-table3"/>
                  <table frame="hsides" rules="groups">
                    <colgroup span="1">
                      <col align="left" span="1"/>
                      <col align="char" char="." span="1"/>
                      <col align="char" char="." span="1"/>
                      <col align="char" char="." span="1"/>
                      <col align="char" char="." span="1"/>
                      <col align="char" char="." span="1"/>
                      <col align="char" char="." span="1"/>
                      <col align="char" char="." span="1"/>
                      <col align="char" char="." span="1"/>
                      <col align="char" char="." span="1"/>
                      <col align="char" char="." span="1"/>
                      <col align="char" char="." span="1"/>
                    </colgroup>
                    <thead>
                      <tr>
                        <th rowspan="1" colspan="1"/>
                        <th align="center" rowspan="1" colspan="1">Week 0 Mean (SD) (n = 27)</th>
                        <th align="center" rowspan="1" colspan="1">Week 1 Mean (SD) (n = 25)</th>
                        <th align="center" rowspan="1" colspan="1">Week 2 Mean (SD) (n = 23)</th>
                        <th align="center" rowspan="1" colspan="1">Week 3 Mean (SD) (n = 25)</th>
                        <th align="center" rowspan="1" colspan="1">Week 4 Mean (SD) (n = 23)</th>
                        <th align="center" rowspan="1" colspan="1">Week 5 Mean (SD) (n = 22)</th>
                        <th align="center" rowspan="1" colspan="1">Week 6 Mean (SD) (n = 23)</th>
                        <th align="center" rowspan="1" colspan="1">Week 8 Mean (SD) (n = 21)</th>
                        <th align="center" rowspan="1" colspan="1">Week 10 Mean (SD) (n = 19)</th>
                        <th align="center" rowspan="1" colspan="1">Week 14 Mean (SD) (n = 24)</th>
                        <th align="center" rowspan="1" colspan="1">
                          <italic>P</italic>
                        </th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td rowspan="1" colspan="1">Q1: Intensity</td>
                        <td rowspan="1" colspan="1">4.96 (3.19)</td>
                        <td rowspan="1" colspan="1">3.96 (3.26)</td>
                        <td rowspan="1" colspan="1">3.43 (2.92)</td>
                        <td rowspan="1" colspan="1">3.52 (2.57)</td>
                        <td rowspan="1" colspan="1">2.17 (2.29)</td>
                        <td rowspan="1" colspan="1">2.64 (2.65)</td>
                        <td rowspan="1" colspan="1">2.3 (2.42)</td>
                        <td rowspan="1" colspan="1">1.86 (1.85)</td>
                        <td rowspan="1" colspan="1">1.95 (2.32)</td>
                        <td rowspan="1" colspan="1">2.54 (2.84)</td>
                        <td rowspan="1" colspan="1">&lt;.0001</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Q2: Sharp</td>
                        <td rowspan="1" colspan="1">4.56 (3.38)</td>
                        <td rowspan="1" colspan="1">3.36 (3.09)</td>
                        <td rowspan="1" colspan="1">2.82 (2.98)</td>
                        <td rowspan="1" colspan="1">2.56 (2.48)</td>
                        <td rowspan="1" colspan="1">2.09 (2.35)</td>
                        <td rowspan="1" colspan="1">1.91 (2.37)</td>
                        <td rowspan="1" colspan="1">1.96 (2.2)</td>
                        <td rowspan="1" colspan="1">1.52 (1.89)</td>
                        <td rowspan="1" colspan="1">1.74 (2.56)</td>
                        <td rowspan="1" colspan="1">1.67 (2.37)</td>
                        <td rowspan="1" colspan="1">&lt;.0001</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Q3: Hot</td>
                        <td rowspan="1" colspan="1">3.48 (3.17)</td>
                        <td rowspan="1" colspan="1">2.12 (2.39)</td>
                        <td rowspan="1" colspan="1">1.39 (1.77)</td>
                        <td rowspan="1" colspan="1">1.48 (2.35)</td>
                        <td rowspan="1" colspan="1">1.17 (2.17)</td>
                        <td rowspan="1" colspan="1">1.86 (2.73)</td>
                        <td rowspan="1" colspan="1">1 (1.83)</td>
                        <td rowspan="1" colspan="1">0.9 (1.64)</td>
                        <td rowspan="1" colspan="1">1.21 (2.37)</td>
                        <td rowspan="1" colspan="1">0.58 (1.25)</td>
                        <td rowspan="1" colspan="1">&lt;.0001</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Q4: Dull</td>
                        <td rowspan="1" colspan="1">4.19 (2.89)</td>
                        <td rowspan="1" colspan="1">3.04 (2.85)</td>
                        <td rowspan="1" colspan="1">2.91 (2.45)</td>
                        <td rowspan="1" colspan="1">3.16 (2.76)</td>
                        <td rowspan="1" colspan="1">2.09 (1.98)</td>
                        <td rowspan="1" colspan="1">2.09 (2.49)</td>
                        <td rowspan="1" colspan="1">2.09 (2.15)</td>
                        <td rowspan="1" colspan="1">1.9 (1.84)</td>
                        <td rowspan="1" colspan="1">1.74 (2.05)</td>
                        <td rowspan="1" colspan="1">1.75 (2.19)</td>
                        <td rowspan="1" colspan="1">&lt;.0001</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Q5: Cold</td>
                        <td rowspan="1" colspan="1">3.33 (3.24)</td>
                        <td rowspan="1" colspan="1">2.2 (2.41)</td>
                        <td rowspan="1" colspan="1">2.43 (2.68)</td>
                        <td rowspan="1" colspan="1">1.88 (2.49)</td>
                        <td rowspan="1" colspan="1">1.83 (2.29)</td>
                        <td rowspan="1" colspan="1">1.64 (1.87)</td>
                        <td rowspan="1" colspan="1">1.26 (1.79)</td>
                        <td rowspan="1" colspan="1">1.48 (2.32)</td>
                        <td rowspan="1" colspan="1">1.38 (2.14)</td>
                        <td rowspan="1" colspan="1">1.42 (1.93)</td>
                        <td rowspan="1" colspan="1">&lt;.0001</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Q6: Sensitive</td>
                        <td rowspan="1" colspan="1">3.44 (3.8)</td>
                        <td rowspan="1" colspan="1">2.52 (3.07)</td>
                        <td rowspan="1" colspan="1">1.87 (2.65)</td>
                        <td rowspan="1" colspan="1">2.16 (2.81)</td>
                        <td rowspan="1" colspan="1">2.09 (3.04)</td>
                        <td rowspan="1" colspan="1">2.05 (2.77)</td>
                        <td rowspan="1" colspan="1">1.61 (2.31)</td>
                        <td rowspan="1" colspan="1">1.81 (2.46)</td>
                        <td rowspan="1" colspan="1">1.37 (2.19)</td>
                        <td rowspan="1" colspan="1">1.79 (2.86)</td>
                        <td rowspan="1" colspan="1">.0001</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Q7: Itchy</td>
                        <td rowspan="1" colspan="1">1.44 (2.22)</td>
                        <td rowspan="1" colspan="1">0.88 (1.39)</td>
                        <td rowspan="1" colspan="1">0.74 (1.36)</td>
                        <td rowspan="1" colspan="1">1 (1.68)</td>
                        <td rowspan="1" colspan="1">0.96 (1.58)</td>
                        <td rowspan="1" colspan="1">0.73 (1.39)</td>
                        <td rowspan="1" colspan="1">0.69 (1.36)</td>
                        <td rowspan="1" colspan="1">0.71 (1.23)</td>
                        <td rowspan="1" colspan="1">0.53 (1.02)</td>
                        <td rowspan="1" colspan="1">0.54 (1.22)</td>
                        <td rowspan="1" colspan="1">.021</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Q9: Unpleasant</td>
                        <td rowspan="1" colspan="1">5.63 (3.16)</td>
                        <td rowspan="1" colspan="1">4.4 (3.06)</td>
                        <td rowspan="1" colspan="1">3.83 (2.84)</td>
                        <td rowspan="1" colspan="1">3.12 (2.4)</td>
                        <td rowspan="1" colspan="1">2.74 (2.51)</td>
                        <td rowspan="1" colspan="1">3.09 (2.71)</td>
                        <td rowspan="1" colspan="1">2.61 (2.5)</td>
                        <td rowspan="1" colspan="1">2.33 (2.24)</td>
                        <td rowspan="1" colspan="1">2.32 (2.16)</td>
                        <td rowspan="1" colspan="1">2.96 (2.49)</td>
                        <td rowspan="1" colspan="1">&lt;.0001</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Q10a: Deep</td>
                        <td rowspan="1" colspan="1">4.96 (3.64)</td>
                        <td rowspan="1" colspan="1">3.56 (3.15)</td>
                        <td rowspan="1" colspan="1">3.26 (3.03)</td>
                        <td rowspan="1" colspan="1">2.96 (2.65)</td>
                        <td rowspan="1" colspan="1">2.26 (2.7)</td>
                        <td rowspan="1" colspan="1">2.81 (3.09)</td>
                        <td rowspan="1" colspan="1">2 (2.61)</td>
                        <td rowspan="1" colspan="1">2 (2.02)</td>
                        <td rowspan="1" colspan="1">1.68 (2.16)</td>
                        <td rowspan="1" colspan="1">3 (3.21)</td>
                        <td rowspan="1" colspan="1">.0001</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Q10b: Surface</td>
                        <td rowspan="1" colspan="1">4.96 (3.32)</td>
                        <td rowspan="1" colspan="1">3.04 (2.75)</td>
                        <td rowspan="1" colspan="1">3.22 (2.61)</td>
                        <td rowspan="1" colspan="1">2.16 (1.84)</td>
                        <td rowspan="1" colspan="1">2.04 (2.31)</td>
                        <td rowspan="1" colspan="1">2.18 (2.3)</td>
                        <td rowspan="1" colspan="1">1.69 (1.84)</td>
                        <td rowspan="1" colspan="1">2.24 (2.12)</td>
                        <td rowspan="1" colspan="1">2.16 (2.25)</td>
                        <td rowspan="1" colspan="1">2.04 (2.14)</td>
                        <td rowspan="1" colspan="1">&lt;.0001</td>
                      </tr>
                    </tbody>
                  </table>
                </alternatives>
                <table-wrap-foot>
                  <fn id="table-fn4-1534735418788667">
                    <p>Abbreviation: NPS, Neuropathy Pain Scale.</p>
                  </fn>
                </table-wrap-foot>
              </table-wrap>
            </sec>
            <sec sec-type="discussion" id="section8-1534735418788667">
              <title>Discussion</title>
              <p>In this study, we report that acupuncture reduced multiple symptoms associated with
BIPN. The self-reported, well-validated FACT/GOG-Ntx and NPS scores were analyzed to
delineate which individual BIPN symptoms benefitted the most from acupuncture. The
FACT/GOG-Ntx sensory subscale had the lowest score at baseline (indicating the most
severe neuropathy symptoms) and the highest score at posttreatment week 14
(indicating the least neuropathy symptoms) with a mean score increase of 4.4 points
(<italic>P</italic> &lt; .0001). This suggests sensory subscale symptoms may
benefit the most from acupuncture. Of the individual symptoms within the sensory
subscale, numbness and tingling sensations in both hands and feet and discomfort in
feet benefitted the most from acupuncture (all 3 symptoms have <italic>P</italic>
&lt; .0001). With improvement of feet symptoms, the individual symptom score for
difficulty walking also significantly increased and improved (<italic>P</italic>
&lt; .0001). The NPS scores decreased across all 10 evaluated items, indicating
acupuncture treatment comprehensively alleviates neuropathic pain symptoms. The most
significant reductions were observed in pain intensity, sharp pain, hot pain,
unpleasantness of pain, and surface pain.</p>
              <p>Our study identified individual symptoms that were alleviated the most by
acupuncture. The result confirmed that acupuncture might be beneficial for certain
symptoms associated with BIPN. Numbness and tingling in hands and feet, typically
debilitating, improved the most along with trouble walking. Other symptoms that
significantly improved after acupuncture were pain intensity and both hot and sharp
pain sensations. These results could help clinicians recommend acupuncture based on
patients’ individual BIPN symptoms.</p>
              <p>Notably, our study has the following advantages: acupuncture was the only
intervention allowed during the study, and the study did not permit initiating
and/or adjusting pharmacological intervention or other interventions like
reflexology. The literature suggests that acupuncture in combination with
reflexology can reduce both sensory and motor neuropathy equally.<sup><xref rid="bibr13-1534735418788667" ref-type="bibr">13</xref></sup> However, our study demonstrated that sensory symptoms were alleviated the
most with improvement of gross motor symptoms, but not fine motor skills.</p>
              <p>There are a few possible explanations to support our findings. Multiple studies have
reported that acupuncture can stimulate both Aδ and C fibers, which can be damaged
from chemotherapy.<sup><xref rid="bibr21-1534735418788667" ref-type="bibr">21</xref><xref rid="bibr22-1534735418788667" ref-type="bibr"/><xref rid="bibr23-1534735418788667" ref-type="bibr"/>-<xref rid="bibr24-1534735418788667" ref-type="bibr">24</xref></sup> Aδ and C fiber disruption from
chemotherapy can cause peripheral neuropathy symptoms such as pain, burning,
numbness, and tingling, as well as gait instabilities, weakness, hyperesthesia,
allodynia, and dysregulation of temperature discrimination.<sup><xref rid="bibr23-1534735418788667" ref-type="bibr">23</xref>,<xref rid="bibr24-1534735418788667" ref-type="bibr">24</xref></sup> Itchiness and
unpleasant sensations have been found to also be associated with dysfunction of the
same fiber types.<sup><xref rid="bibr25-1534735418788667" ref-type="bibr">25</xref></sup> Acupuncture can directly suppress diffuse noxious inhibitory controls and
lead to activation of Aδ and C fibers and transmission in neurons of the spinal
dorsal horn or trigeminal caudalis.<sup><xref rid="bibr26-1534735418788667" ref-type="bibr">26</xref></sup> Achievement of de qi sensation is a principal of acupuncture that served as
the indicator for minimal stimulation level in our study. Studies have suggested
that Aδ and C fibers are involved during the de qi sensation and the signal
integration into the central nervous system may contribute to the effectiveness of
acupuncture for BIPN.<sup><xref rid="bibr27-1534735418788667" ref-type="bibr">27</xref></sup></p>
              <p>Another possible mechanism is through the activation of neurotrophic factors. For
example, neurotrophins are important regulators in the development of both the
peripheral and central nervous system,<sup><xref rid="bibr28-1534735418788667" ref-type="bibr">28</xref></sup> and bortezomib can interfere with neurotrophins and prevent nerve growth
factor–mediated neuronal survival.<sup><xref rid="bibr29-1534735418788667" ref-type="bibr">29</xref></sup> Another neurotrophic factor, brain-derived neurotrophic factor (BDNF), has
been found to be inversely associated with neuropathic pain in animals.<sup><xref rid="bibr30-1534735418788667" ref-type="bibr">30</xref></sup> There is evidence to suggest that acupuncture can upregulate BDNF expression
and activate BDNF signaling pathways.<sup><xref rid="bibr31-1534735418788667" ref-type="bibr">31</xref></sup> Further investigations in acupuncture and neuron regulatory factors are
warranted to fully elucidate underlying mechanism(s).</p>
              <p>The NPS scores have been utilized to analyze the effects of opioids on reducing
diabetic neuropathy symptoms, and results showed that oxycodone did not change
pain-related pruritus, cold, or sensitive symptoms.<sup><xref rid="bibr32-1534735418788667" ref-type="bibr">32</xref></sup> In our study, NPS scores acupuncture significantly reduced NPS scores for
sensitivity, cold pain, and other pain based on NPS scores. Similar studies also
demonstrated the effectiveness of acupuncture but the exact mechanism of action
remains unknown.<sup><xref rid="bibr33-1534735418788667" ref-type="bibr">33</xref></sup> A future randomized control trial comparing opioids and acupuncture could
compare the differences between opioids and acupuncture in relieving neuropathic
pain and related symptoms.</p>
              <p>We would like to acknowledge the limitations of our study. The sample size (n = 27)
of the study was small; thus, a larger study is needed to truly understand the
impact of acupuncture on peripheral neuropathy symptoms. Additionally, this is a
single-arm trial rather than a randomized controlled study, and we could not rule
out the placebo effect or regression to the mean effect.</p>
              <p>In conclusion, our study provides interesting data suggesting that acupuncture could
be particularly beneficial for patients who have BIPN-associated sensory and
pain-related symptoms. Further randomized controlled studies are needed to determine
the effectiveness of acupuncture to treat BIPN.</p>
            </sec>
          </body>
          <back>
            <fn-group>
              <fn fn-type="other">
                <p><bold>Authors’ Note:</bold> The funding sources had no involvement in the study design; collection, analysis,
and interpretation of data; writing of the report; or decision to submit the
article for publication.</p>
              </fn>
              <fn fn-type="COI-statement">
                <p><bold>Declaration of Conflicting Interests:</bold> The author(s) declared no potential conflicts of interest with respect to the
research, authorship, and/or publication of this article.</p>
              </fn>
              <fn fn-type="financial-disclosure">
                <p><bold>Funding:</bold> The author(s) disclosed receipt of the following financial support for the
research, authorship, and/or publication of this article: This study was funded
in part by a Memorial Sloan Kettering Cancer Center P30 Grant (P30-CA008748).
This study was also funded in part by a R21CA173263 (Ting Bao).</p>
              </fn>
              <fn fn-type="other">
                <p><bold>ORCID iDs:</bold> W. Iris Zhi <inline-graphic xlink:href="10.1177_1534735418788667-img1.jpg"/>
<ext-link ext-link-type="uri" xlink:href="https://orcid.org/0000-0003-4263-7272">https://orcid.org/0000-0003-4263-7272</ext-link></p>
                <p>Evan Ingram <inline-graphic xlink:href="10.1177_1534735418788667-img1.jpg"/>
<ext-link ext-link-type="uri" xlink:href="https://orcid.org/0000-0002-3019-8455">https://orcid.org/0000-0002-3019-8455</ext-link></p>
              </fn>
            </fn-group>
            <ref-list>
              <title>References</title>
              <ref id="bibr1-1534735418788667">
                <label>1</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farguhar-Smith</surname><given-names>P</given-names></name><name><surname>Brown</surname><given-names>MRD</given-names></name></person-group><article-title>Persistent pain in cancer survivors:
pathogenesis and treatment options</article-title>. <source>Pain Clin
Updates</source>.
<year>2016</year>;<volume>24</volume>:<fpage>8</fpage>.</mixed-citation>
              </ref>
              <ref id="bibr2-1534735418788667">
                <label>2</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mateos</surname><given-names>MV</given-names></name><name><surname>San Miguel</surname><given-names>JF.</given-names></name></person-group><article-title>Bortezomib in multiple myeloma</article-title>. <source>Best
Pract Res Clin Haematol</source>.
<year>2007</year>;<volume>20</volume>:<fpage>701</fpage>-<lpage>715</lpage>.<pub-id pub-id-type="pmid">18070714</pub-id></mixed-citation>
              </ref>
              <ref id="bibr3-1534735418788667">
                <label>3</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Richardson</surname><given-names>PG</given-names></name><name><surname>Briemberg</surname><given-names>H</given-names></name><name><surname>Jagannath</surname><given-names>S</given-names></name><etal>et al</etal></person-group><article-title>Frequency, characteristics, and reversibility of
peripheral neuropathy during treatment of advanced multiple myeloma with
bortezomib</article-title>. <source>J Clin Oncol</source>.
<year>2006</year>;<volume>24</volume>:<fpage>3113</fpage>-<lpage>3120</lpage>.<pub-id pub-id-type="pmid">16754936</pub-id></mixed-citation>
              </ref>
              <ref id="bibr4-1534735418788667">
                <label>4</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seretny</surname><given-names>M</given-names></name><name><surname>Currie</surname><given-names>GL</given-names></name><name><surname>Sena</surname><given-names>ES</given-names></name><etal>et al</etal></person-group><article-title>Incidence, prevalence, and predictors of
chemotherapy-induced peripheral neuropathy: a systematic review and
meta-analysis</article-title>. <source>Pain</source>.
<year>2014</year>;<volume>155</volume>:<fpage>2461</fpage>-<lpage>2470</lpage>.<pub-id pub-id-type="pmid">25261162</pub-id></mixed-citation>
              </ref>
              <ref id="bibr5-1534735418788667">
                <label>5</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kerckhove</surname><given-names>N</given-names></name><name><surname>Collin</surname><given-names>A</given-names></name><name><surname>Conde</surname><given-names>S</given-names></name><name><surname>Chaleteix</surname><given-names>C</given-names></name><name><surname>Pezet</surname><given-names>D</given-names></name><name><surname>Balayssac</surname><given-names>D.</given-names></name></person-group><article-title>Long-term effects, pathophysiological mechanisms, and risk
factors of chemotherapy-induced peripheral neuropathies: a comprehensive
literature review</article-title>. <source>Front Pharmacol</source>.
<year>2017</year>;<volume>8</volume>:<fpage>86</fpage>.<pub-id pub-id-type="pmid">28286483</pub-id></mixed-citation>
              </ref>
              <ref id="bibr6-1534735418788667">
                <label>6</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>MR</given-names></name><name><surname>Ramirez</surname><given-names>JD</given-names></name><name><surname>Farquhar-Smith</surname><given-names>P.</given-names></name></person-group><article-title>Pain in cancer survivors</article-title>. <source>Br J
Pain</source>.
<year>2014</year>;<volume>8</volume>:<fpage>139</fpage>-<lpage>153</lpage>.<pub-id pub-id-type="pmid">26516548</pub-id></mixed-citation>
              </ref>
              <ref id="bibr7-1534735418788667">
                <label>7</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Albers</surname><given-names>JW</given-names></name><name><surname>Chaudhry</surname><given-names>V</given-names></name><name><surname>Cavaletti</surname><given-names>G</given-names></name><name><surname>Donehower</surname><given-names>RC.</given-names></name></person-group><article-title>Interventions for preventing neuropathy caused by cisplatin and
related compounds</article-title>. <source>Cochrane Database Syst
Rev</source>.
<year>2014</year>;(<issue>3</issue>):<fpage>CD005228</fpage>.<pub-id pub-id-type="pmid">24687190</pub-id></mixed-citation>
              </ref>
              <ref id="bibr8-1534735418788667">
                <label>8</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Piccolo</surname><given-names>J</given-names></name><name><surname>Kolesar</surname><given-names>JM.</given-names></name></person-group><article-title>Prevention and treatment of chemotherapy-induced peripheral
neuropathy</article-title>. <source>Am J Health Syst Pharm</source>.
<year>2014</year>;<volume>71</volume>:<fpage>19</fpage>-<lpage>25</lpage>.<pub-id pub-id-type="pmid">24352178</pub-id></mixed-citation>
              </ref>
              <ref id="bibr9-1534735418788667">
                <label>9</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bailey</surname><given-names>A</given-names></name><name><surname>Wingard</surname><given-names>D</given-names></name><name><surname>Allison</surname><given-names>M</given-names></name><name><surname>Summers</surname><given-names>P</given-names></name><name><surname>Calac</surname><given-names>D.</given-names></name></person-group><article-title>Acupuncture treatment of diabetic peripheral neuropathy in an
American Indian community</article-title>. <source>J Acupunct Meridian
Stud</source>.
<year>2017</year>;<volume>10</volume>:<fpage>90</fpage>-<lpage>95</lpage>.<pub-id pub-id-type="pmid">28483190</pub-id></mixed-citation>
              </ref>
              <ref id="bibr10-1534735418788667">
                <label>10</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>W</given-names></name><name><surname>Dean-Clower</surname><given-names>E</given-names></name><name><surname>Doherty-Gilman</surname><given-names>A</given-names></name><name><surname>Rosenthal</surname><given-names>DS.</given-names></name></person-group><article-title>The value of acupuncture in cancer care</article-title>.
<source>Hematol Oncol Clin North Am</source>.
<year>2008</year>;<volume>22</volume>:<fpage>631</fpage>-<lpage>648</lpage>.<pub-id pub-id-type="pmid">18638692</pub-id></mixed-citation>
              </ref>
              <ref id="bibr11-1534735418788667">
                <label>11</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bao</surname><given-names>T</given-names></name><name><surname>Goloubeva</surname><given-names>O</given-names></name><name><surname>Pelser</surname><given-names>C</given-names></name><etal>et al</etal></person-group><article-title>A pilot study of acupuncture in treating
bortezomib-induced peripheral neuropathy in patients with multiple
myeloma</article-title>. <source>Integr Cancer Ther</source>.
<year>2014</year>;<volume>13</volume>:<fpage>396</fpage>-<lpage>404</lpage>.<pub-id pub-id-type="pmid">24867959</pub-id></mixed-citation>
              </ref>
              <ref id="bibr12-1534735418788667">
                <label>12</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abuaisha</surname><given-names>BB</given-names></name><name><surname>Costanzi</surname><given-names>JB</given-names></name><name><surname>Boulton</surname><given-names>AJ.</given-names></name></person-group><article-title>Acupuncture for the treatment of chronic painful peripheral
diabetic neuropathy: a long-term study</article-title>. <source>Diabetes Res
Clin Pract</source>.
<year>1998</year>;<volume>39</volume>:<fpage>115</fpage>-<lpage>121</lpage>.<pub-id pub-id-type="pmid">9597381</pub-id></mixed-citation>
              </ref>
              <ref id="bibr13-1534735418788667">
                <label>13</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ben-Horin</surname><given-names>I</given-names></name><name><surname>Kahan</surname><given-names>P</given-names></name><name><surname>Ryvo</surname><given-names>L</given-names></name><name><surname>Inbar</surname><given-names>M</given-names></name><name><surname>Lev-Ari</surname><given-names>S</given-names></name><name><surname>Geva</surname><given-names>R.</given-names></name></person-group><article-title>Acupuncture and reflexology for chemotherapy-induced peripheral
neuropathy in breast cancer</article-title>. <source>Integr Cancer
Ther</source>.
<year>2017</year>;<volume>16</volume>:<fpage>258</fpage>-<lpage>262</lpage>.<pub-id pub-id-type="pmid">28150504</pub-id></mixed-citation>
              </ref>
              <ref id="bibr14-1534735418788667">
                <label>14</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garcia</surname><given-names>MK</given-names></name><name><surname>Cohen</surname><given-names>L</given-names></name><name><surname>Guo</surname><given-names>Y</given-names></name><etal>et al</etal></person-group><article-title>Electroacupuncture for
thalidomide/bortezomib-induced peripheral neuropathy in multiple myeloma: a
feasibility study</article-title>. <source>J Hematol Oncol</source>.
<year>2014</year>;<volume>7</volume>:<fpage>41</fpage>.<pub-id pub-id-type="pmid">24886772</pub-id></mixed-citation>
              </ref>
              <ref id="bibr15-1534735418788667">
                <label>15</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greenlee</surname><given-names>H</given-names></name><name><surname>Crew</surname><given-names>KD</given-names></name><name><surname>Capodice</surname><given-names>J</given-names></name><etal>et al</etal></person-group><article-title>Randomized sham-controlled pilot trial of weekly
electro-acupuncture for the prevention of taxane-induced peripheral
neuropathy in women with early stage breast cancer</article-title>.
<source>Breast Cancer Res Treat</source>.
<year>2016</year>;<volume>156</volume>:<fpage>453</fpage>-<lpage>464</lpage>.<pub-id pub-id-type="pmid">27013473</pub-id></mixed-citation>
              </ref>
              <ref id="bibr16-1534735418788667">
                <label>16</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alimi</surname><given-names>D</given-names></name><name><surname>Rubino</surname><given-names>C</given-names></name><name><surname>Pichard-Leandri</surname><given-names>E</given-names></name><name><surname>Fermand-Brule</surname><given-names>S</given-names></name><name><surname>Dubreuil-Lemaire</surname><given-names>ML</given-names></name><name><surname>Hill</surname><given-names>C.</given-names></name></person-group><article-title>Analgesic effect of auricular acupuncture for cancer pain: a
randomized, blinded, controlled trial</article-title>. <source>J Clin
Oncol</source>.
<year>2003</year>;<volume>21</volume>:<fpage>4120</fpage>-<lpage>4126</lpage>.<pub-id pub-id-type="pmid">14615440</pub-id></mixed-citation>
              </ref>
              <ref id="bibr17-1534735418788667">
                <label>17</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>Z</given-names></name><name><surname>Moody</surname><given-names>J</given-names></name><name><surname>Marx</surname><given-names>BL</given-names></name><name><surname>Hammerstrom</surname><given-names>T.</given-names></name></person-group><article-title>Treatment of chemotherapy-induced peripheral neuropathy in
integrative oncology: a survey of acupuncture and oriental medicine
practitioners</article-title>. <source>J Altern Complement Med</source>.
<year>2017</year>;<volume>23</volume>:<fpage>964</fpage>-<lpage>970</lpage>.<pub-id pub-id-type="pmid">28661695</pub-id></mixed-citation>
              </ref>
              <ref id="bibr18-1534735418788667">
                <label>18</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paik</surname><given-names>S</given-names></name><name><surname>Tang</surname><given-names>G</given-names></name><name><surname>Shak</surname><given-names>S</given-names></name><etal>et al</etal></person-group><article-title>Gene expression and benefit of chemotherapy in
women with node-negative, estrogen receptor-positive breast
cancer</article-title>. <source>J Clin Oncol</source>.
<year>2006</year>;<volume>24</volume>:<fpage>3726</fpage>-<lpage>3734</lpage>.<pub-id pub-id-type="pmid">16720680</pub-id></mixed-citation>
              </ref>
              <ref id="bibr19-1534735418788667">
                <label>19</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>HQ</given-names></name><name><surname>Brady</surname><given-names>MF</given-names></name><name><surname>Cella</surname><given-names>D</given-names></name><name><surname>Fleming</surname><given-names>G.</given-names></name></person-group><article-title>Validation and reduction of FACT/GOG-Ntx subscale for
platinum/paclitaxel-induced neurologic symptoms: a gynecologic oncology
group study</article-title>. <source>Int J Gynecol Cancer</source>.
<year>2007</year>;<volume>17</volume>:<fpage>387</fpage>-<lpage>393</lpage>.<pub-id pub-id-type="pmid">17362317</pub-id></mixed-citation>
              </ref>
              <ref id="bibr20-1534735418788667">
                <label>20</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calhoun</surname><given-names>EA</given-names></name><name><surname>Welshman</surname><given-names>EE</given-names></name><name><surname>Chang</surname><given-names>CH</given-names></name><etal>et al</etal></person-group><article-title>Psychometric evaluation of the functional
assessment of cancer therapy/gynecologic oncology group-neurotoxicity
(Fact/GOG-Ntx) questionnaire for patients receiving systemic
chemotherapy</article-title>. <source>Int J Gynecol Cancer</source>.
<year>2003</year>;<volume>13</volume>:<fpage>741</fpage>-<lpage>748</lpage>.<pub-id pub-id-type="pmid">14675309</pub-id></mixed-citation>
              </ref>
              <ref id="bibr21-1534735418788667">
                <label>21</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>X</given-names></name><name><surname>Qin</surname><given-names>Q</given-names></name><name><surname>Yu</surname><given-names>X</given-names></name><etal>et al</etal></person-group><article-title>Acupuncture at heterotopic acupoints facilitates
distal colonic motility via activating M3 receptors and somatic afferent
C-fibers in normal, constipated, or diarrhoeic rats</article-title>.
<source>Neurogastroenterol Motil</source>.
<year>2015</year>;<volume>27</volume>:<fpage>1817</fpage>-<lpage>1830</lpage>.<pub-id pub-id-type="pmid">26459908</pub-id></mixed-citation>
              </ref>
              <ref id="bibr22-1534735418788667">
                <label>22</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>Wu</surname><given-names>L</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><etal>et al</etal></person-group><article-title>Neurobiological mechanism of acupuncture for
relieving visceral pain of gastrointestinal origin</article-title>.
<source>Gastroenterol Res Pract</source>.
<year>2017</year>;<volume>2017</volume>:<fpage>5687496</fpage>.<pub-id pub-id-type="pmid">28243252</pub-id></mixed-citation>
              </ref>
              <ref id="bibr23-1534735418788667">
                <label>23</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tavee</surname><given-names>J</given-names></name><name><surname>Zhou</surname><given-names>L.</given-names></name></person-group><article-title>Small fiber neuropathy: a burning problem</article-title>.
<source>Cleve Clin J Med</source>.
<year>2009</year>;<volume>76</volume>:<fpage>297</fpage>-<lpage>305</lpage>.<pub-id pub-id-type="pmid">19414545</pub-id></mixed-citation>
              </ref>
              <ref id="bibr24-1534735418788667">
                <label>24</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Voortman</surname><given-names>M</given-names></name><name><surname>Fritz</surname><given-names>D</given-names></name><name><surname>Vogels</surname><given-names>OJM</given-names></name><etal>et al</etal></person-group><article-title>Small fiber neuropathy: a disabling and
underrecognized syndrome</article-title>. <source>Curr Opin Pulm
Med</source>.
<year>2017</year>;<volume>23</volume>:<fpage>447</fpage>-<lpage>457</lpage>.<pub-id pub-id-type="pmid">28639956</pub-id></mixed-citation>
              </ref>
              <ref id="bibr25-1534735418788667">
                <label>25</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Potenzieri</surname><given-names>C</given-names></name><name><surname>Undem</surname><given-names>BJ.</given-names></name></person-group><article-title>Basic mechanisms of itch</article-title>. <source>Clin Exp
Allergy</source>.
<year>2012</year>;<volume>42</volume>:<fpage>8</fpage>-<lpage>19</lpage>.<pub-id pub-id-type="pmid">21645138</pub-id></mixed-citation>
              </ref>
              <ref id="bibr26-1534735418788667">
                <label>26</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawakita</surname><given-names>K</given-names></name><name><surname>Okada</surname><given-names>K.</given-names></name></person-group><article-title>Acupuncture therapy: mechanism of action, efficacy, and safety: a
potential intervention for psychogenic disorders?</article-title><source>Biopsychosocial Med</source>.
<year>2014</year>;<volume>8</volume>:<fpage>4</fpage>.</mixed-citation>
              </ref>
              <ref id="bibr27-1534735418788667">
                <label>27</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>W</given-names></name><name><surname>Benharash</surname><given-names>P.</given-names></name></person-group><article-title>Significance of “Deqi” response in acupuncture treatment: myth or
reality</article-title>. <source>J Acupunct Meridian Stud</source>.
<year>2014</year>;<volume>7</volume>:<fpage>186</fpage>-<lpage>189</lpage>.<pub-id pub-id-type="pmid">25151451</pub-id></mixed-citation>
              </ref>
              <ref id="bibr28-1534735418788667">
                <label>28</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siniscalco</surname><given-names>D</given-names></name><name><surname>Giordano</surname><given-names>C</given-names></name><name><surname>Rossi</surname><given-names>F</given-names></name><name><surname>Maione</surname><given-names>S</given-names></name><name><surname>de Novellis</surname><given-names>V.</given-names></name></person-group><article-title>Role of neurotrophins in neuropathic pain</article-title>.
<source>Curr Neuropharmacol</source>.
<year>2011</year>;<volume>9</volume>:<fpage>523</fpage>-<lpage>529</lpage>.<pub-id pub-id-type="pmid">22654713</pub-id></mixed-citation>
              </ref>
              <ref id="bibr29-1534735418788667">
                <label>29</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Broyl</surname><given-names>A</given-names></name><name><surname>Corthals</surname><given-names>SL</given-names></name><name><surname>Jongen</surname><given-names>JL</given-names></name><etal>et al</etal></person-group><article-title>Mechanisms of peripheral neuropathy associated
with bortezomib and vincristine in patients with newly diagnosed multiple
myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4
trial</article-title>. <source>Lancet Oncol</source>.
<year>2010</year>;<volume>11</volume>:<fpage>1057</fpage>-<lpage>1065</lpage>.<pub-id pub-id-type="pmid">20864405</pub-id></mixed-citation>
              </ref>
              <ref id="bibr30-1534735418788667">
                <label>30</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Geng</surname><given-names>SJ</given-names></name><name><surname>Liao</surname><given-names>FF</given-names></name><name><surname>Dang</surname><given-names>WH</given-names></name><etal>et al</etal></person-group><article-title>Contribution of the spinal cord BDNF to the
development of neuropathic pain by activation of the NR2B-containing NMDA
receptors in rats with spinal nerve ligation</article-title>. <source>Exp
Neurol</source>.
<year>2010</year>;<volume>222</volume>:<fpage>256</fpage>-<lpage>266</lpage>.<pub-id pub-id-type="pmid">20079352</pub-id></mixed-citation>
              </ref>
              <ref id="bibr31-1534735418788667">
                <label>31</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>D</given-names></name><name><surname>De La Pena</surname><given-names>I</given-names></name><name><surname>Lin</surname><given-names>L</given-names></name><name><surname>Zhou</surname><given-names>SF</given-names></name><name><surname>Borlongan</surname><given-names>CV</given-names></name><name><surname>Cao</surname><given-names>C.</given-names></name></person-group><article-title>The neuroprotective role of acupuncture and activation of the
BDNF signaling pathway</article-title>. <source>Int J Mol Sci</source>.
<year>2014</year>;<volume>15</volume>:<fpage>3234</fpage>-<lpage>3252</lpage>.<pub-id pub-id-type="pmid">24566146</pub-id></mixed-citation>
              </ref>
              <ref id="bibr32-1534735418788667">
                <label>32</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jensen</surname><given-names>MP</given-names></name><name><surname>Friedman</surname><given-names>M</given-names></name><name><surname>Bonzo</surname><given-names>D</given-names></name><name><surname>Richards</surname><given-names>P.</given-names></name></person-group><article-title>The validity of the neuropathic pain scale for assessing diabetic
neuropathic pain in a clinical trial</article-title>. <source>Clin J
Pain</source>.
<year>2006</year>;<volume>22</volume>:<fpage>97</fpage>-<lpage>103</lpage>.<pub-id pub-id-type="pmid">16340598</pub-id></mixed-citation>
              </ref>
              <ref id="bibr33-1534735418788667">
                <label>33</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elmariah</surname><given-names>SB.</given-names></name></person-group><article-title>Adjunctive management of itch in atopic
dermatitis</article-title>. <source>Dermatol Clin</source>.
<year>2017</year>;<volume>35</volume>:<fpage>373</fpage>-<lpage>394</lpage>.<pub-id pub-id-type="pmid">28577806</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
